Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193081 | 0.84 | KIF11 (0.43) | KIF11CYP11B1CYP11B2SMN1; SMN2NFE2L2 | |
| SCHEMBL19464698 | 0.82 | RIPK1 (0.41) | CYP11B1CYP11B2NFE2L2 | |
| SCHEMBL23821044 | 0.80 | ESR1 (0.35) | KIF11 | |
| SCHEMBL26326946 | 0.79 | KIF11 (0.40) | KIF11CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL441485 | 0.79 | KIF11 (0.44) | KIF11CYP11B1CYP11B2SMN1; SMN2NFE2L2 | |
| SCHEMBL6090490 | 0.78 | KIF11 (0.42) | KIF11CYP11B1CYP11B2SMN1; SMN2NFE2L2 | |
| SCHEMBL19464679 | 0.78 | HDAC3 (0.39) | — | |
| SCHEMBL19965727 | 0.78 | KIF11 (0.40) | KIF11SMN1; SMN2 | |
| SCHEMBL14640087 | 0.77 | KIF11 (0.42) | KIF11CYP11B1CYP11B2SMN1; SMN2NFE2L2 | |
| SCHEMBL30893085 | 0.76 | TRPA1 (0.46) | SMN1; SMN2ACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111931-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KIF11 1807/4885CYP11B1 10/4885CYP11B2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.